Drug intelligence / Profile preview

ADG116 + toripalimab

Development stage: Unknown
Lead developer: Adagene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**ADG116 + toripalimab** is an investigational combination therapy consisting of ADG116, a fully human monoclonal antibody that inhibits CTLA-4 (Cytotoxic T-Lymphocyte-Associated Antigen 4), and toripalimab, a monoclonal antibody targeting PD-1 (programmed cell death protein 1). ADG116 blocks CTLA-4, enhancing the activation and proliferation of T cells, thereby promoting antitumor immune responses. Toripalimab inhibits PD-1, preventing immune evasion by tumor cells and boosting anti-cancer immunity. The combination is designed to synergistically augment immune checkpoint blockade in patients with advanced or metastatic solid tumors[1][3].

Other names: anti-CTLA-4 antibody + anti-PD-1 antibody (toripalimab)

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ADG116 + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADG116 + toripalimab.

Explore the full profile